Intraocular pressure after intravitreal injection of XXXX implant for @entity1103 resulting from @entity2994 .

@entity1 @entity3853 @entity2994 @entity726 @entity1103 @entity619 @entity2790 @entity288
PURPOSE: A recognized side effect of @entity288 @entity3853 ( @entity3853 ) is the onset of @entity2790 . The aim of our study was to analyze changes in short-term intraocular pressure (IOP) after @entity3853 of sustained-release @entity619 implant in order to provide an appropriate monitoring scheme. METHODS: In this retrospective study, the charts of 44 eyes of 42 @entity1 treated by @entity3853 of @entity619 implant for @entity1103 resulting from @entity2994 were reviewed. The IOP measurements were performed at baseline and at 15 minutes, 7 days (D7), 1 month (M1), 2 months (M2), and 4 months (M4) after @entity3853 . RESULTS: Mean IOP was 13.4    2.5 mm Hg at baseline. Twelve eyes out of 44 (27.3%) were treated with antihypertensive eyedrops for a well-controlled @entity726 at baseline. Following @entity3853 , mean IOP was 11.5    3.6 mm Hg at 15 minutes, 14.7    3.1 mm Hg at D7, 16.4    7.0 mm Hg at M1, 19.3    7.9 mm Hg at M2, and 13.5    3.1 mm Hg at M4. An IOP >= 25 mm Hg or increased by 10 mm Hg or more was not observed in any eye at 15 minutes, D7, or M4 after @entity3853 , but in 8.6% of cases at M1 and in 25% at M2. CONCLUSIONS: It seems reasonable to perform the first IOP monitoring 1 month after @entity3853 of @entity619 implant and at each efficacy assessment visit (M2, M4). Special attention should be given to @entity1 at risk, such as @entity726 @entity1 . An IOP measurement immediately after @entity3853 and in the following days (1 week) does not seem to be appropriate on a routine basis.
